Curis (NASDAQ:CRIS) Announces Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Curis (NASDAQ:CRIS) announced its quarterly earnings data on Monday. The biotechnology company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11, Zacks reports. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. The firm had revenue of $2.70 million during the quarter, compared to analyst estimates of $2.04 million.

Curis Price Performance

NASDAQ:CRIS traded down $0.64 during mid-day trading on Tuesday, reaching $1.46. The stock had a trading volume of 289,004 shares, compared to its average volume of 93,750. The stock has a market cap of $12.36 million, a P/E ratio of -0.19 and a beta of 3.49. The business’s 50 day moving average is $3.01 and its 200 day moving average is $3.86. Curis has a fifty-two week low of $1.40 and a fifty-two week high of $17.49.

Analyst Ratings Changes

Several analysts recently commented on CRIS shares. StockNews.com started coverage on shares of Curis in a report on Saturday. They set a “hold” rating for the company. HC Wainwright decreased their target price on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.